Target RWE has appointed Ed Seguine as chief executive officer.

The company, which focuses on generating longitudinal real-world data across therapeutic areas such as liver disease, was acquired in January by Highlander Health. The acquisition marked the first for Highlander Health Partners, a division led by co-founders Amy Abernethy and Brad Hirsch.

As CEO, Seguine will lead efforts to expand the impact of real-world data in clinical practice and research. His remit includes enhancing evidence-generation strategies and improving the use of data to support treatment decisions.

Commenting on the appointment, Brad Hirsch said the leadership change signals a new phase for Target RWE. “We’re excited to bring Ed onboard to help advance Target RWE’s efforts to reimagine evidence generation,” he said.

Amy Abernethy added that the company’s data infrastructure and industry relationships provide a strong foundation for building prospective clinical trials. “We look forward to partnering with Ed to demonstrate how high-quality longitudinal real-world data can support better understanding of which interventions work, for whom, and when,” she said.

Before joining Target RWE, Seguine was CEO at Elemental Machines. He previously founded Clinical Ink and held leadership roles at Fast Track Systems and Eli Lilly.

“This is an opportunity to build tools that extend drug utility and make real-world evidence more actionable,” said Seguine. “Target RWE’s data assets and industry partnerships offer real potential to solve practical problems in areas like hepatology, dermatology and gastrointestinal disease.”